Arrowhead Insider Buy Signals Confidence as Gene‑Silencing Stock Surges 429% YTD
Arrowhead Pharmaceuticals insider activity shows board member Matthew Cohen buying 11,882 shares at zero cost, reflecting confidence in the company’s RNAi platform and potential Phase III breakthrough.
- ARROWHEAD PHARMACEUTICALS IN
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
4 minutes to read